<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978874</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 03808</org_study_id>
    <nct_id>NCT00978874</nct_id>
  </id_info>
  <brief_title>Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer</brief_title>
  <official_title>[F18]EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find&#xD;
      oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and&#xD;
      help plan the best treatment.&#xD;
&#xD;
      PURPOSE: This trial is studying fluorine F 18 EF5 PET/CT imaging to see how well it works in&#xD;
      finding hypoxia in tumor cells of patients with locally advanced or recurrent/metastatic&#xD;
      cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine if the presence and heterogeneity of hypoxia can be detected by fluorine F&#xD;
           18 EF5 binding in tumors during PET/CT imaging in patients with newly diagnosed or&#xD;
           recurrent carcinoma of the cervix.&#xD;
&#xD;
        -  To determine if fludeoxyglucose F 18 uptake correlates with fluorine F 18 EF5 uptake.&#xD;
&#xD;
        -  To assess the relationship between fluorine F 18 EF5 uptake and disease-free and overall&#xD;
           survival.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease stage (locally advanced vs recurrent or&#xD;
      metastatic disease).&#xD;
&#xD;
      Patients receive fluorine F 18 EF5 IV followed by PET/CT imaging from the base of skull to&#xD;
      upper thigh at baseline and during radiotherapy or chemotherapy (i.e., at 3-4 weeks after the&#xD;
      initiation of radiotherapy or after the 4th, 5th, or 6th course of chemotherapy). Patients&#xD;
      also undergo fludeoxyglucose F 18 PET/CT imaging within 7 to 10 days of the second fluorine F&#xD;
      18 EF5 scan.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then annually&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI is no longer with our institution&#xD;
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 4, 2013</completion_date>
  <primary_completion_date type="Actual">September 4, 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship Between Fluorine F 18 EF5 Uptake and Disease-free Survival and Overall Survival</measure>
    <time_frame>7 years</time_frame>
    <description>The study was terminated and no data are available to be reported</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorine F 18 EF5</intervention_name>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of carcinoma of the cervix meeting 1 of the following criteria:&#xD;
&#xD;
               -  Pathologically confirmed, newly diagnosed stage IB-IVA (locally advanced) disease&#xD;
&#xD;
               -  Imaging evidence of recurrent or metastatic disease&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 cm on anatomic imaging&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  WBC &gt; 2,000/mm³&#xD;
&#xD;
          -  Platelet count &gt; 90,000/mm³&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reactions attributed to Flagyl (metronidazole)&#xD;
&#xD;
          -  No other condition or personal circumstance that, in the judgment of the Investigator,&#xD;
             may interfere with the collection of complete, good-quality data&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilie Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <results_first_submitted>September 23, 2020</results_first_submitted>
  <results_first_submitted_qc>June 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <disposition_first_submitted>April 21, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 28, 2020</disposition_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>fludeoxyglucose F 18&#xD;
fluorine F 18 EF5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">The study was terminated and no data are available to be reported</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">The study was terminated and no data are available to be reported</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated and despite all possible attempts to contact the PI/study team, no data are available to be reported</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>fludeoxyglucose F 18&#xD;
fluorine F 18 EF5</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relationship Between Fluorine F 18 EF5 Uptake and Disease-free Survival and Overall Survival</title>
        <description>The study was terminated and no data are available to be reported</description>
        <time_frame>7 years</time_frame>
        <population>The study was terminated and no data are available to be reported</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>fludeoxyglucose F 18&#xD;
fluorine F 18 EF5</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Fluorine F 18 EF5 Uptake and Disease-free Survival and Overall Survival</title>
          <description>The study was terminated and no data are available to be reported</description>
          <population>The study was terminated and no data are available to be reported</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-Cause Mortality, Serious, and Other [Not Including Serious] Adverse Events were not monitored/assessed</time_frame>
      <desc>The study was terminated and no data are available to be reported</desc>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>fludeoxyglucose F 18&#xD;
fluorine F 18 EF5</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lilie Lin, MD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-662-6515</phone>
      <email>lin@xrt.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

